For 2025, Alnylam is projecting product revenue of between $2.05 billion to $2.25 billion, which would be a 31% increase at midpoint. Amvuttra Alnylam Pharmaceuticals ATTR Onpattro BridgeBio ...
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR ...
Reports Q4 revenue $593.17M, consensus $580.62M. “2024 was another year of impressive execution for Alnylam (ALNY), generating product revenues of over $1.6 billion, reflecting growth of 33% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback